Tivantinib and Regorafenib for the Treatment of Liver Cancer

Clinical Pearls

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.

• Tivantinib is in phase III development for liver cancer
• A phase II study comparing tivantinib to placebo showed no dramatic benefit in all-comers
• An analysis showed high MET expression was associated with worse prognosis, and high MET patients saw benefit from tivantinib versus low MET
• Regorafenib has shown activity in colorectal cancer and GIST
• A phase II study of regorafenib demonstrated provocative survival data for patients who have progressed on sorafenib